Parathyroid hormone (1-84) plus alendronate was not better than monotherapy with either agent in postmenopausal osteoporosis

May 2004
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p62
Academic Journal
This article presents a study to determine the effectiveness of parathyroid hormone (PTH) plus alendronate and monotherapy with either agent for increasing bone mineral density, in postmenopausal women with osteoporosis. 238 postmenopausal women 55 to 85 years of age, who had osteoporosis defined as a T score of less than -2, history of postmenopausal fracture, or maternal history of hip fracture, were taken for the study. Analysis was by intention to treat. Increase in total hip areal bone mineral density (BMD) was greater in the combination group than in the PTH group. Decrease in areal BMD at the distal one third of the radius was greater in the PTH group than in the combination group.


Related Articles

  • Parathyroid hormone (1-84) plus alendronate was not better than monotherapy with either agent in postmenopausal osteoporosis: COMMENTARY. Jamal, Sophie // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p62 

    Alendronate inhibits bone resorption, increases bone mineral density (BMD), and reduces fracture risk in men and women with osteoporosis. Parathyroid hormone therapy (PTH) administered daily stimulates bone formation and increases BMD in both men and postmenopausal women with osteoporosis. PTH...

  • Influence of reproductive factors on hip fracture risk in Chinese women. Dezheng Huo; Diane S. Lauderdale; Liming Li // Osteoporosis International;Aug2003, Vol. 14 Issue 8, p694 

    To assess the relationships between reproductive factors and the risk of hip fractures in postmenopausal Chinese women, the authors analyzed data from a matched case-control study conducted in the Beijing metropolitan area among women aged 50 years and older. One hundred and fifty-six cases who...

  • Review: Human parathyroid hormone reduces fractures and increases bone mineral density in severe osteoporosis.  // ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p71 

    The article focuses on a study related to effectiveness of human parathyroid hormone (hPTH) in patients with severe osteoporosis. The study involved randomized controlled trials that compared hPTH with placebo or an active comparator in postmenopausal women or men with osteoporosis. The study...

  • Parathyroid Hormone (1-84) and Risk for Spinal Fractures in Women with Osteoporosis.  // Annals of Internal Medicine;3/6/2007, Vol. 146 Issue 5, pI20 

    The article offers the simplified information concerning parathyroid hormone and risk for spinal fractures in women with osteoporosis to be better understood by patients. It is stated that people with osteoporosis have bones that become less dense and more expected to break. Details regarding...

  • Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review. Gallacher, S. J.; Dixon, T. // Calcified Tissue International;Dec2010, Vol. 87 Issue 6, p469 

    The objective of this systematic review was to examine the influence of treatments for postmenopausal osteoporosis (parathyroid hormone [PTH], bisphosphonates, strontium ranelate, and denosumab) on bone quality and discuss the clinical implications. Most bone-quality data for PTH is from...

  • Effectiveness of teriparatide treatment on back pain-related functional limitations in individuals affected by severe osteoporosis: a prospective pilot study. Iolascon, Giovanni; Gimigliano, Francesca; Malavolta, Nazzarena; Tarantino, Umberto; Fornari, Rachele; Greco, Emanuela; Di Pietro, Gioconda; Gimigliano, Raffaele; Lenzi, Andrea; Resmini, Giuseppina; Migliaccio, Silvia // Clinical Cases in Mineral & Bone Metabolism;Sep-Dec20212, Vol. 9 Issue 3, p161 

    Introduction. Vertebral fractures have been associated with back pain, functional limitations and reduced health-related quality of life (HRQoL). Teriparatide is the first effective anabolic agent that demonstrated to significantly reduce the risk of vertebral fracture by 65%, as compared to...

  • Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Fogelman, I.; Fordham, J. N.; Fraser, W. D.; Spector, T. D.; Christiansen, C.; Morris, S. A.; Fox, J. // Calcified Tissue International;Aug2008, Vol. 83 Issue 2, p85 

    Treatment of postmenopausal osteoporosis (PMO) is based primarily on antiresorptive agents, including hormone replacement therapy (HT). To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone...

  • Vitamin D and intact PTH status in patients with hip fracture. Sakuma, M.; Endo, N.; Oinuma, T.; Hayami, T.; Endo, E.; Yazawa, T.; Watanabe, K.; Watanabe, S. // Osteoporosis International;Nov2006, Vol. 17 Issue 11, p1608 

    The prevalence of hypovitaminosis D in patients with acute hip fracture was examined in a population on Sado Island in Japan. There were 85 cases of hip fracture among this population in 2004, giving an overall incidence of hip fracture of 121.4 per 100,000 population per year. This study...

  • Zometa and hip fractures.  // Clinical Cardiology Alert;Nov2007, Vol. 26 Issue 11, p2 

    The article reports on a clinical trial in which a 5 mg infusion of zoledronic acid within 90 days of hip fracture reduced the risk of new fractures and improved survival. The drug was found effective at reducing vertebral, hip and non-vertebral fractures in women with osteoporosis. It mentions...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics